GSK PLC - GSK StarRatingValueLabel_5Jay Lee - Senior Equity Analyst - Morningstar Inc.

Last Price
1,345.50
Day Change
-0.50|-0.04%

As of 16/04/2025
16:35:06 BST | GBX  Minimum 15 Minutes Delay.

Bid/OfferDay RangeVolume90d Ave VolMkt Cap
1,334.00 - 1,374.001,327.00 - 1,352.006,578,42810,108,11854.56Bil
Last Close52 Week RangeP/EYield %ISIN
1,346.001,242.50 - 1,823.5021.644.53GB00BN7SWP63

Morningstar's Take GSK

As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and expansive list of patent-protected drugs create a wide economic moat, in our opinion.

Fair Value Estimate

Premium

Uncertainty

Premium

Economic Moat

Premium

Financial Strength

Financial Strength
There is no one analyst in which a Quantitative Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.’s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here.

Total Returns 15/04/2025

 Chg (%)  
GSK PLC-10.92 
FTSE 100 TR GBP-4.10
 
Financials
202220232024
more...
Income Statement
Turnover29,324.0030,328.0031,376.00
Operating Profit6,729.007,345.005,542.00
Net Profit4,921.005,308.002,951.00
Reported EPS109.20119.9062.20
Balance Sheet
Current Assets20,671.0018,568.0016,994.00
Non Current Assets39,377.0040,361.0042,466.00
Total Assets60,146.0059,005.0059,463.00
Current Liabilities22,810.0021,068.0021,697.00
Total Liabilities50,050.0046,210.0046,377.00
Total Equity10,096.0012,795.0013,086.00
Cash Flow
Operating Cash Flow8,713.008,096.007,861.00
Net Change in Cash-546.00-468.00599.00

Regulatory News

DateAuthor Headline
05/03/2025James Gard Top FTSE 100 UK Dividend Paying Stocks
Updated for March 2025: Reporting season brought a raft of dividend increases.
06/11/2024Christopher Johnson Can The GRANOLAS Stocks End 2024 On A High?
Amid market volatility and falling interest rates, Europe‘s Magnificent Seven have delivered a mixed performance, but this could all change.
11/10/2024Jay Lee GSK: Zantac Settlement Was Big, But Removes Uncertainty
Pharmaceutical company to pay more than USD 2 billion to settle lawsuits over heartburn drug
Director Dealings
TradedActionNotifierPriceAmountValue
more...
11/04/2025PurchaseDr. Hal V Barron17.0658990.00
11/04/2025PurchaseMr. Charles A. Bancroft17.063485,937.00
11/04/2025PurchaseDr. Vishal Sikka17.061963,344.00
11/04/2025PurchaseDr. Jesse Goodman, M.D.,M.P.H.17.0644751.00

Company Profile

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Sector

Healthcare

Industry

Drug Manufacturers - General

Stock Style

Large-Value

Fiscal Year Ends

December

Employees

68,629

Next Event 30/04/2025

First Quarter Results
Ratios
Comp
PER (E)23.50
Div Yld (E)4.17
PEG (E)0.37
ROCE10.90
Op Mrgn17.70
EPS Grwth-0.30
Dividends
PreviousLatest
more...
Record Date15/11/2421/02/25
Ex-Div14/11/2420/02/25
Paid09/01/2510/04/25
Amnt15.0016.00
Directors
more...
Non-Executive DirectorDr. Hal V Barron
Non-Executive Director, ChairmanSir Jonathan Richard Symonds CBE
Non-Executive Director, Senior Independent DirectorMr. Charles A. Bancroft
Company SecretaryMrs. Victoria Anne Whyte
Non-Executive DirectorMs. Wendy Becker
Non-Executive DirectorDr. Vishal Sikka
Executive Director, Chief Executive OfficerDame Emma N. Walmsley
Executive Director, Chief Financial OfficerMs. Julie Brown
Non-Executive DirectorDr. Jesse Goodman, M.D.,M.P.H.
Non-Executive DirectorMs. Elizabeth McKee Anderson
Non-Executive DirectorDr. Anne Beal
Non-Executive DirectorDr. Harry C Dietz
Non-Executive DirectorDr. Jeannie Lee
Jay Lee - Senior Equity Analyst - Morningstar Inc.
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures